American Journal of Obstetrics and Gynecology
ResearchObstetricsFirst-trimester maternal plasma cell-free fetal DNA and preeclampsia
Section snippets
Study population
This was a case-control study in singleton pregnancies. In our center, we perform screening for hypertensive complications of pregnancy in women who attend for their routine first hospital visit in pregnancy. In this visit, which is held at 11+0-13+6 weeks of gestation, all women have an ultrasound scan (1) to confirm gestational age from the measurement of the fetal crown-rump length, (2) to diagnose any major fetal abnormalities, and (3) to measure fetal nuchal translucency thickness as part
Results
Maternal blood was collected between March 2006-March 2007 and analyzed at a median interval of 20.6 months (range, 13.3–25.0 months). The maternal characteristics of each of the outcome groups are compared in Table 2. In the preeclampsia group, compared with the control group, the BMI was higher, and more women had a personal or family history of preeclampsia and chronic hypertension. In the preeclampsia group, the median uterine artery PI was significantly higher than in the control group,
Comment
The findings of this study confirm the association of preeclampsia with increased cffDNA in maternal blood and demonstrate that (1) the increased cffDNA is evident from 11-13 weeks of gestation and (2) the level of cffDNA is associated with the degree of impairment in placental perfusion and severity of preeclampsia. Significantly increased levels of cffDNA and uterine artery PI were observed in severe early-onset preeclampsia that required delivery at <34 weeks of gestation rather than in
References (39)
- et al.
Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia
Am J Obstet Gynecol
(2001) - et al.
Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction
Am J Obstet Gynecol
(2003) - et al.
Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia
Am J Obstet Gynecol
(2004) - et al.
UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation: Fetal Medicine Foundation First Trimester Screening Group
Lancet
(1998) - et al.
The classification and definition of the hypertensive disorders of pregnancy
Am J Obstet Gynecol
(1988) - et al.
Disturbed feto-maternal cell traffic in preeclampsia
Obstet Gynecol
(1998) - et al.
Elevation in erythroblast count in maternal blood before the onset of preeclampsia
Am J Obstet Gynecol
(2001) Make every mother and child count: World Health Report, 2005
(2005)Diagnosis and management of preeclampsia and eclampsia: ACOG practice bulletin no: 33
Obstet Gynecol
(2002)
The physiological response of the vessels of the placental bed to normal pregnancy
J Pathol Bacteriol
Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants
BJOG
Placental bed spiral arteries in the hypertensive disorders of pregnancy
BJOG
Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia
Ultrasound Obstet Gynecol
Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies
BMJ
Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia
Clin Chem
Quantitative analysis of fetal DNA in maternal plasma in pathological conditions associated with placental abnormalities
Ann N Y Acad Sci
Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome as a complication of preeclampsia in pregnant women increases the amount of cell-free fetal and maternal DNA in maternal plasma and serum
Clin Chem
Fetal DNA clearance from maternal plasma is impaired in preeclampsia
Clin Chem
Cited by (82)
Obstetrical, perinatal, and genetic outcomes associated with nonreportable prenatal cell-free DNA screening results
2023, American Journal of Obstetrics and GynecologyCell-free fetal DNA impairs trophoblast migration in a TLR9-dependent manner and can be reversed by hydroxychloroquine
2023, Journal of Reproductive ImmunologyInflammation in preterm birth: Novel mechanism of preterm birth associated with innate and acquired immunity
2022, Journal of Reproductive ImmunologyImplications of non-invasive prenatal testing for identifying and managing high-risk pregnancies
2021, European Journal of Obstetrics and Gynecology and Reproductive BiologyCitation Excerpt :The ongoing interest in the use of ffDNA as a predictive marker or diagnostic test for adverse pregnancy outcomes is because of the need to better understand disease processes and to enable improved treatments to be developed and appropriately targeted. When considering usefulness in clinical practice, several authors have suggested that ffDNA does not enhance currently available pre-eclampsia screening.[9,21] Some have come to this conclusion for PTB too.[43]
Cell-free fetal DNA at 11-13 weeks of gestation is not altered in complicated pregnancies
2024, Biomedical ReportsPredicting the onset of preeclampsia by longitudinal monitoring of metabolic changes throughout pregnancy with Raman spectroscopy
2024, Bioengineering and Translational Medicine
Cite this article as: Sifakis S, Zaravinos A, Maiz N, et al. First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol 2009;201:472.e1-7.
This study was supported by a Grant from the Fetal Medicine Foundation (UK Charity no. 1037116).